Related by context. All words. (Click for frequent words.) 72 T#I [002] 72 chronic myeloid leukemia CML 70 tyrosine kinase inhibitors 69 BRAF mutation 68 imatinib resistant 67 Gleevec resistant 67 dasatinib Sprycel ® 66 leukemia CLL 66 EGFR inhibitors 66 K ras mutations 66 imatinib Gleevec 66 castration resistant prostate cancer 66 Ph + ALL 65 nucleoside analogues 65 dasatinib 65 EGFR mutation 65 erlotinib Tarceva ® 65 nilotinib 65 leukemia AML 65 epithelial tumors 65 EGFR mutations 65 antibody MAb 65 HGS ETR1 64 mRCC 64 imatinib therapy 64 FLT3 64 GPNMB 64 superficial bladder cancer 64 tyrosine kinase inhibitors TKIs 64 dasatinib Sprycel 64 receptor tyrosine kinase inhibitor 64 OncoVEX GM CSF 64 metastatic malignant melanoma 64 imatinib Gleevec ® 64 chronic myelogenous leukemia CML 63 BCR ABL 63 M#V mutation 63 bevacizumab Avastin ® 63 cytogenetic responses 63 metastatic RCC 63 cell lymphoma CTCL 63 imatinib mesylate Gleevec 63 hematological cancers 63 MPS IVA 63 TTR gene 63 lymphoma CTCL 63 AMN# [001] 63 CCR5 antagonist 63 gastrointestinal stromal tumor GIST 62 metastatic renal cell carcinoma 62 cetuximab Erbitux ® 62 heavily pretreated 62 systemic ALCL 62 CML CP 62 chronic lymphocytic leukemia CLL 62 leukemia ALL 62 KRAS mutations 62 B CLL 62 imatinib mesylate 62 complete cytogenetic 62 complete remissions 62 HBeAg positive patients 62 nilotinib Tasigna ® 62 leukemia CML 62 TELCYTA 62 TKIs 62 evaluable 62 refractory CML 62 myeloproliferative disorders 62 cetuximab Erbitux R 62 ribavirin RBV 62 recurrent NSCLC 62 heavily pretreated patients 62 alkylating agents 62 HER2 positive metastatic breast 62 Ceflatonin 62 idarubicin 62 proteasome inhibitor 62 NNRTIs 61 gastrointestinal stromal tumors 61 hypereosinophilic syndrome 61 HCV infected 61 cytogenetic response 61 huC# DM4 61 FLT3 mutations 61 androgen independent 61 T#I mutant 61 OMAPRO 61 HCV genotypes 61 MKC# MT 61 mapatumumab 61 CBLC# 61 tyrosine kinase inhibitor 61 myelofibrosis polycythemia vera 61 pan HDAC inhibitor 61 MCyR 61 myelodysplastic syndrome MDS 61 TKI therapy 61 mCRC patients 61 biologic therapy 61 metastatic colorectal cancer 61 refractory multiple myeloma 61 IMGN# 61 BRAF V#E mutation 61 situ CIS 61 unresectable 61 trastuzumab Herceptin ® 61 cutaneous T cell 61 humanized antibody 61 myeloproliferative diseases 61 CEQ# 61 gastrointestinal stromal tumors GIST 61 tyrosine kinase inhibitor TKI 61 Xanafide 61 aHUS 61 liver metastases 61 AEG# 61 trans retinoic acid ATRA 61 humanized monoclonal antibody 61 standard chemotherapy regimens 61 evaluable patients 61 NRTIs 61 chlorambucil 61 hormone refractory prostate cancer 60 NSCLC 60 hypomethylating agents 60 cell malignancies 60 metastatic hormone refractory 60 advanced NSCLC 60 BCR ABL mutation 60 familial amyloidotic polyneuropathy FAP 60 NNRTI 60 relapsed SCLC 60 Traficet EN 60 protease inhibitor PI 60 pomalidomide 60 HCV infection 60 stage IIIB 60 relapsed leukemia 60 refractory chronic myeloid 60 anthracycline containing 60 KRAS wild 60 metastatic CRC 60 refractory Hodgkin lymphoma 60 recurrent GBM 60 Omacetaxine 60 EGFR TKI 60 relapsing remitting multiple sclerosis 60 refractory chronic lymphocytic 60 caspofungin 60 prior chemotherapy regimens 60 relapsed refractory multiple myeloma 60 hepatitis C HCV 60 follicular lymphoma 60 metastatic malignant 60 fludarabine 60 inhibitor RG# 60 imatinib 60 LTBI 60 ponatinib 60 CD# monoclonal antibody 60 alkylating agent 60 chronic eosinophilic leukemia 60 myeloid 60 cutaneous T 60 SOD1 gene 60 mutated KRAS gene 60 refractory AML 60 refractory CLL 60 Chronic Myeloid Leukemia CML 60 pegylated interferon alpha 60 patients evaluable 60 histone deacetylase HDAC inhibitor 60 octreotide 60 CYT# potent vascular disrupting 60 Epratuzumab 60 recurrent glioblastoma multiforme 60 GBM tumors 60 Zolinza 60 PNP inhibitor 60 BRAF mutations 60 elacytarabine 60 HER2/neu 60 partial remissions 60 Bezielle 60 docetaxel Taxotere ® 60 decitabine 60 bendamustine 60 TLR9 agonist 60 remission induction 60 nilotinib Tasigna 60 pediatric acute lymphoblastic 60 alefacept 60 multidrug resistance 60 metastatic GIST 60 achieve sustained virologic 60 Myelodysplastic Syndrome MDS 60 anti EGFR antibody 60 docetaxel chemotherapy 60 HBsAg 60 taxane 60 ribavirin therapy 60 IV metastatic melanoma 60 neuroendocrine cancers 60 familial ALS 59 relapsed ALL 59 Cloretazine 59 oral prodrug 59 cilengitide 59 PKC# 59 Bcr Abl T#I mutation 59 acute myeloid leukemia AML 59 multiple myeloma MM 59 humanized anti 59 orally administered inhibitor 59 BCR ABL inhibitors 59 refractory NSCLC 59 SCCHN 59 castrate resistant prostate cancer 59 nucleoside analogs 59 Ofatumumab 59 HER2 overexpression 59 refractory gout 59 Epidermal Growth Factor Receptor 59 huN# DM1 59 cytotoxic chemotherapy 59 HCV protease 59 idiopathic pulmonary fibrosis IPF 59 hepatocellular carcinoma HCC 59 oblimersen 59 relapsed AML 59 lymphoid malignancies 59 YONDELIS 59 interferon IFN 59 trabectedin 59 IV NSCLC 59 dacarbazine DTIC 59 HQK 59 sunitinib Sutent ® 59 dosing cohorts 59 NRTI 59 alvespimycin 59 Phase Ib study 59 pancreatic adenocarcinoma 59 calcineurin inhibitors 59 taxane chemotherapy 59 CR# vcMMAE 59 castrate resistant 59 non metastatic osteosarcoma 59 Hodgkin lymphoma NHL 59 metastatic castration resistant 59 CANCIDAS 59 IMA# 59 EGFR tyrosine kinase inhibitors 59 Kit CD# positive 59 HBeAg negative 59 relapsed refractory 59 Irinotecan 59 Ph + CML 59 SinuNase TM 59 medullary thyroid cancer 59 carcinoembryonic antigen CEA 59 RNAi therapeutic targeting 59 Telintra 59 Pegasys ® 59 thalidomide Thalomid 59 Her2 59 NNRTI resistance 59 vemurafenib 59 LHRH 59 cMET 59 unresectable stage 59 Proxinium TM 59 DMARDs 59 tafamidis 59 anti TNF alpha 59 lupus nephritis 59 INCB# [001] 59 fluoropyrimidine 59 disease modifying antirheumatic 59 HBeAg positive 59 NS4A 59 galiximab 59 HRPC 59 Aflibercept 59 genotypic resistance 59 polymerase inhibitor 59 DMARDS 59 HCV genotype 1 59 metastatic renal cell 59 ALK inhibitors 59 HuMax CD4 59 imatinib resistance 59 CCX# 59 JAK1 59 MET amplification 59 prostate cancer HRPC 58 acute myelogenous leukemia AML 58 lumiliximab 58 interferon therapy 58 Tamibarotene 58 systemic fungal infections 58 evaluable subjects 58 chronic HCV 58 gefitinib Iressa 58 EGFRvIII 58 Bortezomib 58 metastatic melanoma 58 chronic myeloid 58 myelodysplastic myeloproliferative diseases 58 anthracyclines taxanes 58 depsipeptide 58 pancreatic neuroendocrine tumors 58 eosinophilic asthma 58 Acute Myeloid Leukemia AML 58 OXi# 58 TELINTRA 58 KIT mutations 58 chronic HCV infection 58 acute promyelocytic leukemia 58 Ozarelix 58 GISTs 58 bortezomib 58 forodesine 58 HGS ETR2 58 targeting CD# 58 Panzem R NCD 58 JAK3 58 ABSSSI 58 HCV SPRINT 58 immunomodulatory therapy 58 anti TNF 58 gemcitabine carboplatin 58 luteinizing hormone releasing 58 CD3 monoclonal antibody 58 Reverset 58 Amigal 58 PDX pralatrexate 58 chronic HBV infection 58 protein kinase inhibitor 58 azacytidine 58 refractory CTCL 58 HDACi 58 bevirimat 58 complete cytogenetic response 58 ALK inhibitor 58 HCV 58 atypical hemolytic uremic syndrome 58 TREANDA 58 NRTI resistance 58 KRAS mutation 58 pegylated interferon alfa 2a 58 ovarian carcinoma 58 MAGE A3 58 pertuzumab 58 small molecule inhibitors 58 Metastatic Colorectal Cancer 58 chemotherapy regimens 58 VFEND 58 HCD# [002] 58 IMC A# 58 untreated metastatic melanoma 58 Seliciclib 58 HGS ETR1 mapatumumab 58 IGF 1R 58 CMV disease 58 HSP# inhibitor 58 NS#/#A protease 58 activating EGFR mutations 58 polycythemia vera PV 58 nucleoside 58 VAPRISOL 58 colorectal liver metastases 58 activating mutations 58 SCIg 58 polymerase inhibitors 58 Chronic Lymphocytic Leukemia CLL 58 idiopathic thrombocytopenic purpura ITP 58 MAGE A3 ASCI 58 elotuzumab 58 micafungin 58 Herceptin trastuzumab 58 Valortim R 58 Bcr Abl mutations 58 BRAF V# mutation 58 basal cell carcinoma BCC 58 HCV RESPOND 2 58 refractory cutaneous T 58 dacarbazine 58 Hepatocellular Carcinoma HCC 58 EZN 58 Pemetrexed 58 relapsed GBM 58 antiviral therapy 58 Elotuzumab 58 selective modulator 58 trastuzumab Herceptin R 58 anticancer therapy 58 radezolid 58 chemokine receptors 58 lung metastases 58 M2 subunit 58 Cloretazine ® 58 amrubicin 58 Uricase PEG 58 LY# [003] 58 phase IIb clinical 58 vinca alkaloid 58 hepatitis C genotype 58 BENLYSTA TM 58 Sudhir Agrawal D.Phil 58 T2DM 58 TBC# 58 prostate cancer CRPC 58 CRp 58 UPLYSO 58 solid tumors 58 rALLy 58 KRAS oncogene 58 CCyR 58 Sapacitabine 58 glufosfamide 58 nucleotide analog 57 lamivudine 57 previously untreated follicular 57 Imatinib 57 multi kinase inhibitor 57 sorafenib Nexavar 57 EGFr 57 CLL SLL 57 GW# [003] 57 EpCAM 57 IV melanoma 57 ALN TTR 57 Velcade bortezomib 57 platinum refractory 57 carboplatin paclitaxel 57 ceftazidime 57 leukemic stem cells 57 alpha folate receptor 57 Doxil ® 57 virus HCV infection 57 Daclizumab 57 colon carcinoma 57 telaprevir VX 57 vinca alkaloids 57 pegylated liposomal doxorubicin 57 refractory metastatic 57 PI3K inhibitor 57 Pharmacokinetics PK 57 Crizotinib 57 Alemtuzumab 57 tigecycline 57 anti leukemic 57 mCRC 57 ganetespib 57 Ceflatonin R 57 PEGylated interferon beta 1a 57 adriamycin 57 glioblastoma multiforme GBM 57 refractory acute myeloid 57 cancer mCRC 57 RH1 57 anticancer therapies 57 interferon alfa 57 CCR5 tropic 57 Radezolid 57 metastatic CRPC 57 Fludarabine 57 CCR5 tropic HIV 57 tumor necrosis 57 Bcr Abl 57 virological failure 57 investigational humanized monoclonal antibody 57 relapsed multiple myeloma 57 visilizumab 57 TNF inhibitors 57 investigational monoclonal antibody 57 Gleevec imatinib mesylate 57 Aurexis 57 Annamycin 57 Genasense ® 57 BEXXAR 57 ERBB2 57 systemic lupus erythematosus SLE 57 DXL# 57 nonsmall cell lung cancer 57 NPM1 57 Talabostat 57 Fludara 57 Interferon alpha 57 primary humoral immunodeficiency 57 pegylated interferons 57 olaparib 57 romidepsin 57 vWD 57 FOLFIRI 57 metastatic HRPC 57 RhuDex ® 57 ZOLINZA 57 HER-2/neu 57 pancreatic NET 57 KRAS mutations occur 57 Tumor Necrosis Factor 57 rilonacept 57 adenoviral 57 RRMS patients 57 Epstein Barr virus EBV 57 lamivudine refractory patients 57 EGFR activating mutations 57 Triapine 57 ErbB2 positive 57 JAK2 inhibitors 57 myeloproliferative neoplasms 57 preclinically 57 DMARD 57 CanAg 57 HCV polymerase inhibitors 57 indolent NHL 57 seliciclib 57 mTOR inhibitor 57 MT# MEDI 57 Pralatrexate 57 adalimumab Humira 57 hematologic malignancies 57 LRAT 57 talabostat 57 Dasatinib 57 mutated KRAS 57 haematological malignancies 57 investigational therapies 57 recurrent glioblastoma 57 Prodarsan ® 57 virus HCV protease inhibitor 57 JAK inhibitors 57 latent tuberculosis infection 57 breast carcinomas 57 PARP inhibitor 57 JVRS 57 targeted radiotherapeutic 57 metastatic colorectal 57 relapsed MM 57 Enzastaurin 57 DEB# 57 mTOR inhibitors 57 nucleoside analogue 57 selective inhibitor 57 anticancer agents 57 Allovectin 7 R 57 EOquin 57 PEG IFN 57 GRN# 57 SUTENT 57 atypical Hemolytic Uremic Syndrome 57 null responder HCV 57 Chronic Myeloid Leukemia 57 XmAb# 57 Familial Adenomatous Polyposis FAP 57 sodium glucose cotransporter 57 systemic lupus erythematosus 57 esophageal candidiasis 57 follicular lymphoma FL 57 CD# [002] 57 A3 adenosine receptor 57 Janus kinase 57 K RAS 57 CYC# 57 disease modifying 57 OHR/AVR# 57 velafermin 57 follicular NHL 57 molecularly targeted 57 EGFR tyrosine kinase inhibitor 57 Glioblastoma Multiforme 57 oral vancomycin 57 canakinumab 57 UGT#A# 57 Perifosine 57 Sym# 57 essential thrombocythemia 56 Hepatitis C virus HCV 56 Alocrest 56 Li Fraumeni Syndrome 56 tocilizumab 56 gefitinib 56 GRASPA ® 56 IAP inhibitor 56 JAK2 enzyme 56 PROCHYMAL 56 ketolide antibiotic 56 JAK2 V#F 56 Voreloxin 56 irinotecan chemotherapy 56 tumor lysis syndrome 56 relapsing MS 56 glioblastoma 56 diagnosed Ph + 56 interferon alfa 2b 56 grade cervical intraepithelial 56 proteasome inhibitors 56 PD LID 56 HER2 receptor 56 virotherapy 56 AA amyloidosis 56 docetaxel Taxotere R 56 TNF antagonist 56 MDS AML 56 FUS1 56 lenalidomide Revlimid R 56 PRT# 56 dose limiting toxicities 56 HCV replicon 56 K ras 56 TORISEL 56 sJIA 56 prostate cancer CaP 56 tumor antigen 56 efalizumab 56 IIIB NSCLC 56 MCSP respectively 56 LHRH antagonists 56 HSCT 56 omega interferon 56 HBeAg negative patients 56 Navelbine ® 56 neuroblastoma tumors 56 tuberculin skin testing 56 IgG1 antibody 56 TACI Ig 56 Oritavancin 56 crizotinib PF # 56 MabCampath 56 metastatic neuroendocrine tumors 56 Acute Radiation Syndrome ARS 56 lamivudine resistant 56 CTAP# Capsules 56 DLBCL 56 VEGF receptor 56 pegylated alpha interferon 56 CHOP chemotherapy 56 tumor shrinkage 56 Gleevec imatinib 56 invasive candidiasis 56 hypercalcemia 56 refractory PTCL 56 systemic anaplastic large 56 AAV2 56 pancreatic carcinoma 56 Troxatyl 56 potent inhibition 56 HuLuc# 56 Myelofibrosis 56 EGF receptor 56 FGFR2 56 CCR2 56 MEK inhibitors 56 elvucitabine 56 resistant ovarian cancer 56 Her2/neu 56 latent TB infection 56 Vorinostat 56 bortezomib Velcade 56 follicular lymphomas 56 pDCs 56 differentiated thyroid 56 stage IIIb 56 NOMID 56 leukaemias 56 Aplidin R 56 infliximab 56 anaplastic lymphoma kinase ALK 56 HBeAg 56 lintuzumab SGN 56 PLX# 56 lymphocytosis 56 FOLFOX4 56 investigational protease inhibitor 56 Cytolin ® 56 gemcitabine Gemzar 56 Virologic 56 hepatic metastases 56 tumors GIST 56 resectable 56 ara C 56 papillary renal cell carcinoma 56 NS5A 56 SPRYCEL ® 56 ELACYT 56 cisplatin chemotherapy 56 TTR amyloidosis 56 mycophenolate mofetil 56 BARACLUDE ® 56 busulfan 56 glioblastoma tumors 56 Exherin TM 56 PREZISTA r 56 MGd 56 HCV genotype 56 tumor regression 56 malignant pleural mesothelioma 56 IL# PE#QQR 56 vascular disrupting agent 56 metaglidasen 56 EGFR HER2 56 thymoma 56 lapatinib Tykerb 56 relapsing multiple sclerosis 56 PCa 56 transthyretin amyloidosis 56 cetuximab Erbitux 56 rindopepimut 56 TG# [003] 56 hematological malignancies 56 CLL cells 56 Cytoxan 56 temsirolimus 56 breast cancer subtypes 56 bladder carcinoma 56 PANVAC VF 56 doxorubicin HCl liposome injection 56 antisense oligonucleotides 56 synthetic retinoid 56 ALN VSP 56 Tarceva erlotinib 56 achieved PASI 56 hA# 56 castration resistant 56 eribulin mesylate 56 Curaxin CBLC# 56 metastatic disease 56 Phase IIb trials 56 BCG refractory 56 dose cohort 56 Amrubicin 56 vimentin 56 plasma uric acid 56 transcriptase inhibitor NNRTI 56 vWF 56 Philadelphia Chromosome Positive 56 opioid induced constipation OIC 56 acute GvHD 56 hormone LHRH antagonist 56 pegylated 56 HAAH 56 untreated chronic lymphocytic 56 NSCLC tumors 56 immunomodulatory 56 miglustat 56 BCR ABL protein 56 radiation sensitizer 56 CD# antibodies 56 VICTRELIS 56 dosing cohort 56 Phase #b/#a clinical 56 anthracycline taxane 56 antisense drug 56 Campath alemtuzumab 56 operable breast cancer 56 XYOTAX TM 56 invasive aspergillosis 56 HBV vaccine 56 DFMO 56 HCV infections 56 Hodgkin lymphoma HL 56 Evoltra TM 56 CD# antibody [001] 56 fulvestrant 56 CDK inhibitor 56 Tyrima 56 Phase 2a trial 56 cytologically confirmed 56 HGS# 56 chemokine receptor 56 anti angiogenic agents 56 posaconazole 56 JAK2 56 Temsirolimus 56 vinorelbine 56 liposomal formulation 56 angiogenesis inhibitor 56 leukemia APL 56 AP# [003] 56 syngeneic 56 GVAX 56 novel VDA molecule 56 BRAF gene 56 LHRH analogues 56 VEGF inhibitors 56 signal transduction inhibitors 56 chemotherapeutic 56 relapsing remitting 56 relapsed ovarian cancer 56 sorafenib tablets 56 neuropilin 56 nutlin 3a 56 trastuzumab DM1 T DM1 56 AGHD 56 vandetanib 56 recurrent ovarian cancer 55 BCG refractory carcinoma 55 nab paclitaxel 55 Insegia 55 Lenocta 55 MEK inhibitor 55 ErbB 55 amoxicillin clavulanate 55 fusion proteins 55 ganciclovir 55 virologic failure 55 arsenic trioxide 55 completely resected 55 peritoneal carcinomatosis 55 chronic plaque psoriasis 55 formerly LymphoStat B 55 chimeric monoclonal antibody 55 paclitaxel Taxol 55 standard chemotherapy regimen 55 serous ovarian cancer 55 Ph + 55 dexpramipexole 55 hepatocellular carcinomas 55 CIMZIA ™ 55 MGUS 55 systemically administered 55 neoadjuvant chemotherapy 55 taxane resistant 55 calcineurin inhibitor 55 Trastuzumab 55 antimetabolite 55 plasma kallikrein inhibitor 55 Fludara ® 55 Dacogen injection 55 IIa trial 55 FGFR1 55 humanised monoclonal antibody 55 haematologic 55 INCB# [003] 55 sorafenib Nexavar ® 55 xenograft models 55 posterior uveitis 55 TACI mutations 55 Immunohistochemical analysis 55 INT# [002] 55 aflibercept VEGF Trap 55 promoter methylation 55 baminercept 55 entecavir 55 GvHD 55 endocrine therapies 55 mutated BRAF gene 55 trans retinoic acid 55 nonsense mutations 55 talactoferrin 55 Aplidin 55 MGMT gene 55 WT1 55 SAR# [004] 55 MYDICAR ® 55 interferon alpha 55 microtubule targeting 55 APTIVUS r 55 nosocomial pneumonia 55 receptor blocker 55 dirucotide 55 kinase inhibitors 55 MEFs 55 cancer immunotherapies 55 certolizumab 55 selective inhibitors 55 taxane therapy 55 precancerous cervical lesions 55 PRTX 55 TNFa 55 HLA DR 55 XL# XL# 55 Apaziquone 55 Golimumab 55 cytostatic 55 ErbB3 55 peginterferon alfa 55 JAK2 inhibitor 55 vismodegib 55 hematologic 55 immunomodulating 55 prostate adenocarcinoma 55 Personalized Immunotherapy 55 HspE7 55 metastatic gastric 55 refractory ovarian cancer 55 surface glycoprotein 55 MYCN amplification 55 tamibarotene 55 Quinamed 55 Hurthle cell 55 Rituximab 55 neutralizing antibody 55 non squamous NSCLC 55 Viramidine 55 myeloproliferative 55 Li Fraumeni 55 locoregional 55 Phase 2a clinical trials 55 leukemic cells 55 telaprevir dosed 55 Randomized Phase 55 Factor VIIa 55 bevacizumab Avastin 55 Bevacizumab 55 LymphoStat B belimumab 55 PDGF receptor 55 RGB # 55 splenectomized patients 55 Allovectin 7 55 Azixa 55 LEUKINE 55 Pafuramidine 55 PARP inhibitors 55 prostate carcinoma 55 Solid Tumors criteria 55 cytotoxic therapy 55 OMNARIS HFA 55 Azedra 55 glycosylated 55 mycosis fungoides 55 Aviptadil 55 HCV antibody 55 dexamethasone Decadron 55 PXD# 55 nitazoxanide 55 Tarceva TM 55 ON #.Na 55 androgen receptor AR 55 MYLOTARG 55 intranasal formulation 55 Clusterin 55 Clofarabine 55 PEGylated 55 multidrug resistant 55 cabazitaxel 55 colorectal carcinoma 55 lymphoid blast 55 recurrent genital herpes 55 Plicera 55 PEGylated anti 55 Vaprisol 55 squamous cell lung cancer 55 LymphoStat B 55 immunomodulator 55 Alinia 55 voriconazole 55 LHON 55 B7 H3 55 Hedgehog Pathway Inhibitor 55 Surgical resection 55 metastatic lung cancer 55 VQD 55 Degarelix 55 C1 INH 55 hereditary deficiency 55 Atypical Hemolytic Uremic Syndrome 55 Chronic Myelogenous Leukemia 55 daptomycin 55 gemcitabine Gemzar ® 55 bone metastasis 55 Cethromycin 55 adenocarcinomas 55 thrombopoietin 55 TYZEKA 55 activating mutation 55 CTLA 4 55 interferon alfa 2a 55 DOXIL 55 renal cell carcinomas 55 tubulin inhibitor 55 AVASTIN 55 TACE 55 IgA deficiency 55 Dacogen decitabine 55 metastatic kidney 55 bevacizumab Avastin R 55 irinotecan oxaliplatin 55 oncolytic 55 orally bioavailable 55 PhG alpha 1 55 P. aeruginosa 55 K#R [002] 55 CA4P 55 glioma cells 55 hypoxia inducible factor 55 assessing T DM1 55 FOLOTYN ® 55 underwent resection 55 interleukins 55 histologies 55 sunitinib 55 stage IIIB IV 55 serum antibody 55 HPV subtypes 55 Pertuzumab